Test Price
2,800 AED✅ Home Collection Available
CCNO Gene Primary Ciliary Dyskinesia Type 29 Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by Consultant Medical Genetics.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- DHA Certified: Facility License 1143, Dubai Healthcare City.
Test Overview & Methodology
This advanced genetic test analyses the CCNO gene via Next-Generation Sequencing (NGS) to confirm primary ciliary dyskinesia type 29, a hereditary disorder impairing mucociliary clearance and causing chronic ENT and pulmonary infections. It delivers precise molecular diagnosis for tailored management and family planning.
Methodological Comparison
| Feature | DNA Labs UAE CCNO NGS Test | Electron Microscopy / Immunofluorescence |
|---|---|---|
| Methodology | NGS – full gene sequencing & copy number analysis | Ultrastructural ciliary biopsy |
| Precision | >99.9% sensitivity, detects all mutation types including point mutations, indels, CNVs | ~70% sensitivity; may miss subtle or secondary defects |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks, requires fresh sample with strict transport |
| Regulatory Compliance | DHA Approved, ISO 9001:2015, CAP Accredited Pipeline | Limited centers, variable standards across laboratories |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics, I emphasize that identifying a pathogenic CCNO variant via NGS provides a definitive molecular diagnosis for primary ciliary dyskinesia type 29. However, this result must always be interpreted within the full clinical context—including nasal nitric oxide measurements and high-speed video microscopy—for comprehensive patient management. Early genetic confirmation enables tailored airway clearance strategies, targeted vaccination plans, and informed family counselling."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Notes for Patients
Pre-Test Medication Advisory
Continue all prescribed respiratory medications as directed by your physician. Do not alter or discontinue any treatment regimen prior to sample collection without explicit medical consultation. The genetic test does not require medication washout.
Exclusion Criteria & Emergency Red Flags
- Do not proceed with blood draw if: you received a blood transfusion or bone marrow transplant within the last 2 weeks (DNA contamination risk).
- Severe bleeding disorders or current anticoagulation therapy without physician clearance.
- Active infection at venipuncture site.
- Seek immediate emergency care if: you experience acute respiratory distress, cyanosis, or massive hemoptysis unrelated to the test procedure.
Patient FAQ & Clinical Guidance
1. What is the CCNO gene and how does its mutation cause primary ciliary dyskinesia type 29?
Mutations in the CCNO gene disrupt cilia generation, leading to chronic respiratory infections, sinusitis, and reduced fertility. The CCNO gene encodes a protein essential for ciliary biogenesis; when mutated, cilia become dysfunctional or absent, impairing mucus clearance from the airways, ears, and reproductive tract. This comprehensive NGS test detects both known and novel mutations, enabling precise diagnosis and family risk assessment.
2. How accurate is NGS for detecting CCNO mutations compared to traditional ciliary biopsy?
NGS provides >99.9% diagnostic accuracy, identifying point mutations, small indels, and copy number variations that electron microscopy may miss. While ultrastructural biopsy can reveal structural defects, it fails to detect many genetic causes and requires fresh invasive sampling. NGS directly sequences the entire CCNO gene from a simple blood draw, offering a definitive molecular diagnosis with higher sensitivity and specificity.
3. Is this genetic test suitable for children or infants under UAE regulations?
This genetic test is permissible for minors with documented parental consent, fully complying with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019. Genetic testing of children requires informed consent from both parents or legal guardian, accompanied by mandatory pre-test genetic counselling. Our service includes these safeguards under strict confidentiality; no sample is processed without consent.
4. What sample types are accepted and how should I prepare?
We accept peripheral whole blood (venipuncture), extracted DNA, or one drop blood on FTA card collected via VIP Mobile Phlebotomy. Our certified phlebotomist collects samples using strict cold-chain protocol from 8 AM to 11 PM daily. No special preparation is required; continue your regular medications unless specifically advised otherwise by your physician.
5. Will I receive genetic counselling with my results?
Yes, mandatory pre-test and post-test genetic counselling is included with every CCNO gene test. Our Consultant Medical Genetics provides telephonic consultation to explain the implications of your results, discuss inheritance patterns, and guide family screening decisions. This service aligns with Federal Decree-Law No. 4 of 2016 on Medical Liability and best practice standards for genetic testing.
UAE Regulatory & Data Privacy Adherence
Comprehensive Data Protection Framework
DNA Labs UAE operates under strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed solely for diagnostic purposes with explicit patient consent.
Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring every test is accompanied by informed consent, genetic counselling, and adherence to the highest standards of medical ethics. Our DHA Facility License 1143 guarantees regulatory oversight by Dubai Health Authority.
Clinical & Logistical Metadata
| Test Name | CCNO Gene Primary Ciliary Dyskinesia Type 29 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (Venipuncture), Extracted DNA, or FTA Card Blood Spot – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Sequencing & Copy Number Variation Analysis |
| ICD-10-CM Code | J98.4 |
| LOINC Code | 88507-1 |
| DHA Facility License & Laboratory Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians